WilmerHale Leads Epizyme In $250M Follow-On Offering Plans
Epizyme Inc., led by WilmerHale, outlined plans Monday to draw $250 million in a follow-on offering, as the Massachusetts-based cancer treatment developer banks on investor hunger for the space to help...To view the full article, register now.
Already a subscriber? Click here to view full article